Ahmed Abdelaziz Mohamed Hassan
Lecturer
The early effect of dapagliflozin on diastolic function parameters in patients with mid range and reduced ejection fraction heart failure
• 2024
Publication Information
Authors
Ahmed A.Mohammed, Elsayyed A.Eldarky, Ali I.Ateya and Hagar I.Allam
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Cardiovascular mortality and hospitalisation rates were greatest among heart failure (HF) patients with
reduced ejection fraction (HFrEF) according to clinical trial data. Treatment of heart failure with sodium-glucose
transporter-2 inhibitors (SGLT2i) has recently made significant strides [1]. Even in patients with HFrEF, LV
diastolic dysfunction was a separate predictor of outcome [2]. It is essential to identify structural abnormalities
using echocardiography since they have been linked to prognosis in HF and DM patients [3]. Both diabetic and
non-diabetes patients with HF have had their risk of death and hospital readmission decreased by SGLT2is,
according to large-scale randomised studies and meta-analyses [4]. These are part of the global guidelines for the
treatment of heart failure (HF) at the intermediate assessment level [5]. Some theories suggest that SGLT2is
exerts its cardioprotective effects by reversing cardiac remodelling [6] and restoring systolic and diastolic function
reduced ejection fraction (HFrEF) according to clinical trial data. Treatment of heart failure with sodium-glucose
transporter-2 inhibitors (SGLT2i) has recently made significant strides [1]. Even in patients with HFrEF, LV
diastolic dysfunction was a separate predictor of outcome [2]. It is essential to identify structural abnormalities
using echocardiography since they have been linked to prognosis in HF and DM patients [3]. Both diabetic and
non-diabetes patients with HF have had their risk of death and hospital readmission decreased by SGLT2is,
according to large-scale randomised studies and meta-analyses [4]. These are part of the global guidelines for the
treatment of heart failure (HF) at the intermediate assessment level [5]. Some theories suggest that SGLT2is
exerts its cardioprotective effects by reversing cardiac remodelling [6] and restoring systolic and diastolic function